Servier Pharmaceuticals’ Post

NOW ONLINE New Review discusses resistance mechanisms based on cell interactions and secreted soluble factors in the #HematopoieticNiche and provides an overview of niche-related therapeutic targets for #AcuteMyeloidLeukemia therapy 🔓 OPEN ACCESS ➡ https://lnkd.in/dwpD-yzd The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche-related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.

Inhibikase is developing IkT-001Pro to provide people suffering from chronic myelogenous leukemia (CML) with a new and improved, safer alternative to imatinib. Learn about our development of IkT-001Pro for CML here: https://bit.ly/3fMhg8O

In relapsed or refractory NPM1-mutant acute myeloid leukemia, FLT3-ITD co-mutations are common (49%), and prognosis is poor. In this population, only 14% of patients treated with a FLT3 inhibitor achieve a complete remission. KOMET-008 is a phase 1 trial that will examine ziftomenib, a menin inhibitor, in combination with the FLT3 inhibitor gilteritinib in patients with NPM1-m/FLT3 co-mutations. NPM1-m patients without a FLT3 co-mutation and KMT2A-r patients will receive ziftomenib in combination with FLAG-IDA or LDAC. OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

Can be a good clinical target? CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia https://lnkd.in/dSbUPy9E

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases. Despite development of novel treatment options and targeted therapeutics, the 5-year survival rate in adult population is quite low, indicating towards a huge unmet need in AML treatment space. The current infographic concisely highlights the key treatment options for AML and some of the emerging therapeutic stratagems. Access the full infographic here - https://lnkd.in/epixrxas #acutemyeloidleukemia #aml #CancerResearch #TreatmentOptions #EmergingTherapies #infographic #oncofocus

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universitätsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. 💡 Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based #PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of #SJ45566, a potent and orally bioavailable LCK #PROTAC. #Protac #PDC #SmallMolecule #Medchem #Medcinal #FFS #FTE #CDMO #CMC

Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia https://lnkd.in/e-hnxTjt

Asuragen's QuantideX® qPCR PML-RARA Kit offers sensitive and scalable detection of three PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in less than five hours. Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA, these fusions are crucial indicators of acute promyelocytic leukemia (APL), a distinct and aggressive subtype of acute myeloid leukemia (AML). Learn more: https://bit.ly/45917Ub #Asuragen #qPCR #mygulfscientific #gulfscientificcorporation